The Scottish Medicines Consortium (SMC) approves Tasigna® (nilotinib) for use in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) who are intolerant of or resistant to prior therapies, including current gold standard, Glivec® (imatinib), in the early phase of the disease.
This is really good news for patients living in Scotland who don’t respond to current therapies. It means that chronic stage CML patients will have access to the full range of the best therapies available. This will help those patients who do not respond to Glivec, and give them a chance to live productive and fulfilling lives, something that will be beneficial for both individuals and for society as a whole. Unfortunately patients living in England and Wales are not as fortunate.
